Kymera Investor Day Presentation Deck

Successful Examples of Fragment and Covalent Screens Fragment Based Virtual Optimization X-ray with Fragment Fragment bound X-ray structure Rational design to explore SAR In silico library evaluation & synthesis Rational design to optimize library hits KYMERA HTRF IC50 > 1mM IC50 < 30 μM IC50 < 5 μM IC 50 = < 0.1 μM μΜ MW <400 clogP 0.7 Total # of virtual compounds evaluated Total # of crystal structures Total # of compounds made ©2021 KYMERA THERAPEUTICS, INC. X-ray with Optimized Ligand 40K 18 195 cell_line Covalent Ligand E3 Ligase Hit Finding HCT116 PaTu-8988T HCT116 PaTu-8988T HCT116 PaTu-8988T HCT116 HCT116 CL1 CL26 KYMERA R&D DAY - December 16th, 2021 CL51 CL76 CL101 CL126 AC23 ligand CR < 2 CR >= 2 and CR < 4 CR >= 4 NA AC48 AC73 ACB AC123 AC148 7 128 137 176 Novel covalent ligand to bone marrow-sparing E3 ligase for multiple oncology programs PAGE 93

View entire presentation